Patents by Inventor Robert Craig MELLING

Robert Craig MELLING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR
    Publication number: 20220169638
    Abstract: This invention relates to the compound (2R)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide, and in particular to novel physical forms of the compound, a process for preparing the compound and synthetic intermediates for use in the process, and novel formulations containing the compound, as well as therapeutic uses of the compound.
    Type: Application
    Filed: September 1, 2021
    Publication date: June 2, 2022
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Michael READER, Nicola Elizabeth WILSHER, Mark Henry SAUNDERS, Paul Anthony BAGULEY, Colin Thomas LINDLEY, Robert Craig MELLING, Bozena Ewa ADAMCZYK, Mirka SCARATI
  • 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor
    Patent number: 11142518
    Abstract: This invention relates to the compound (2R)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide, and in particular to novel physical forms of the compound, a process for preparing the compound and synthetic intermediates for use in the process, and novel formulations containing the compound, as well as therapeutic uses of the compound.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: October 12, 2021
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Michael Reader, Nicola Elizabeth Wilsher, Mark Henry Saunders, Paul Anthony Baguley, Colin Thomas Lindley, Robert Craig Melling, Bozena Ewa Adamczyk, Mirka Scarati
  • 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR
    Publication number: 20210101889
    Abstract: This invention relates to the compound (2R)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide, and in particular to novel physical forms of the compound, a process for preparing the compound and synthetic intermediates for use in the process, and novel formulations containing the compound, as well as therapeutic uses of the compound.
    Type: Application
    Filed: April 20, 2018
    Publication date: April 8, 2021
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Michael READER, Nicola Elizabeth WILSHER, Mark Henry SAUNDERS, Paul Anthony BAGULEY, Colin Thomas LINDLEY, Robert Craig MELLING, Bozena Ewa ADAMCZYK, Mirka SCARATI